This checklist helps you gather the key facts about your Depo-Provera use and any diagnosis so you can see whether you may meet common eligibility criteria for a lawsuit. It is not legal advice—a free case review with a law firm can give you an answer specific to your situation.
If you've used Depo-Provera, an injectable contraceptive medication, and later received a diagnosis of a brain tumor called a meningioma, you may be wondering whether you qualify for a lawsuit. This eligibility checklist can help you understand the common criteria used to evaluate Depo-Provera cases and determine whether pursuing a legal claim may be appropriate for your situation.
Understanding the eligibility factors can help you prepare for a case review and understand what information may be needed to evaluate your potential claim. This checklist covers the key factors typically considered in Depo-Provera lawsuit evaluations.
Eligibility Checklist for Depo-Provera Lawsuits
Use this checklist to help determine whether you may qualify for a Depo-Provera lawsuit. While each case is evaluated individually, these factors are commonly considered:
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Duration of Depo-Provera Use - [ ] Used Depo-Provera for five years or more - [ ] Used Depo-Provera for three to five years - [ ] Used Depo-Provera for less than three years - [ ] Unsure of exact duration
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Meningioma Diagnosis - [ ] Diagnosed with meningioma through MRI or CT scan - [ ] Diagnosis confirmed through biopsy or surgery - [ ] Diagnosis occurred during or after Depo-Provera use - [ ] Have medical records documenting the diagnosis
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Timing of Diagnosis - [ ] Diagnosed while still using Depo-Provera - [ ] Diagnosed within five years of stopping Depo-Provera - [ ] Diagnosed more than five years after stopping Depo-Provera - [ ] Unsure of exact timing
Medical Documentation - [ ] Have medical records documenting Depo-Provera use - [ ] Have medical records documenting meningioma diagnosis - [ ] Have records of treatment received - [ ] Can obtain medical records if needed
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Symptoms and Treatment - [ ] Experiencing symptoms related to meningioma - [ ] Required or recommended surgery - [ ] Required or recommended radiation therapy - [ ] Currently under medical monitoring
Understanding Each Eligibility Factor
Each factor in the eligibility checklist plays an important role in evaluating whether you may qualify for a Depo-Provera lawsuit. Understanding what each factor means can help you better assess your situation.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Duration of Use: Women who used Depo-Provera for extended periods, particularly five years or more, may have stronger cases. The risk of meningioma development appears to increase with longer duration of use, so those who received injections over many years may be more likely to qualify.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Meningioma Diagnosis: A confirmed diagnosis of meningioma is typically required. This diagnosis is usually made through imaging studies such as MRI or CT scans, and may be confirmed through biopsy if surgery is performed. The diagnosis should have occurred after a period of Depo-Provera use.
Timing of Diagnosis: The timing between Depo-Provera use and meningioma diagnosis is important. Cases where the diagnosis occurred during or after Depo-Provera use may be more relevant than cases where the diagnosis occurred many years before starting the medication.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Medical Documentation: Having medical records that document both your Depo-Provera use history and your meningioma diagnosis is important. These records help establish the connection between the medication and your condition.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Symptoms and Treatment: The severity of your condition, symptoms experienced, and treatment required may also be factors considered in evaluating your case. However, even asymptomatic meningiomas may qualify depending on other circumstances.
What to Do Next
If you've reviewed the eligibility checklist and believe you may qualify, the next step is to seek a free case review. This initial evaluation can help determine whether your situation meets the criteria for pursuing a legal claim.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationGather Your Information: Before your case review, gather any medical records, documentation of your Depo-Provera use, and information about your meningioma diagnosis. This can help make the review process more efficient.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Contact for a Free Case Review: A free case review is confidential and does not create any obligation on your part. During the review, you'll discuss your Depo-Provera use history, your meningioma diagnosis, and other relevant factors.
Understand the Process: The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Know Your Rights: Understanding your legal rights and options is important. A case review can help you understand what compensation you may be entitled to and what the legal process involves.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitIf you're ready to begin, you can contact us for a free case review. This initial evaluation can help determine whether you may qualify for a Depo-Provera lawsuit.
Common Questions About Eligibility
- Q: Do I need to have used Depo-Provera for a specific amount of time?
- According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
While longer duration of use (five years or more) may strengthen a case, there's no absolute minimum requirement. Each case is evaluated individually based on its specific circumstances.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
- Q: What if I'm not sure when I started using Depo-Provera?
- Medical records and pharmacy records may help establish your use history. A case review can help determine what documentation might be available and whether it's sufficient to evaluate your case.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case review- Q: Can I still qualify if my meningioma was diagnosed many years after using Depo-Provera?
- A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The timing between use and diagnosis is important, but there's no specific time limit that automatically disqualifies a case. Each situation is evaluated individually, and statutes of limitations vary by state.
- Q: What if I don't have all my medical records?
- The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Having medical records is helpful but not always required for an initial case review. You can discuss your situation and determine what documentation might be needed to evaluate your case.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
- Q: Do I need to have had surgery to qualify?
- Surgery is not necessarily required to qualify for a lawsuit. Cases are evaluated based on individual circumstances, including the size and location of the meningioma, symptoms experienced, and treatment received or recommended.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityKey points before you file
Eligibility turns on documented Depo-Provera use, a qualifying meningioma diagnosis, and your state's deadline—not on internet checklists alone. Bring pharmacy records and imaging to a free review so counsel can confirm whether your facts fit current litigation criteria.
Scientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Frequently Asked Questions
- Q: How do I know if I qualify for a Depo-Provera lawsuit?
- The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Qualification typically depends on factors such as the duration of Depo-Provera use, the timing of meningioma diagnosis, and having medical documentation. A free case review can help determine whether you may qualify.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
- Q: What information do I need for a case review?
- You'll typically need information about your Depo-Provera use history, your meningioma diagnosis, and any medical records you have. A case review can help determine what additional documentation might be needed.
- Q: Is there a cost for a case review?
- Case reviews are typically conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
- Q: How long does it take to find out if I qualify?
- An initial case review can typically be completed relatively quickly, often within a few days or weeks depending on the complexity of your situation and the availability of medical records.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
- Q: What happens if I qualify?
- If you qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases.
- Q: What happens if I don't qualify?
- If you don't qualify, you'll receive an explanation of why. This can help you understand what factors may have influenced the decision.
Important Disclaimers
Understanding whether you qualify for a Depo-Provera lawsuit is an important first step for women who have used the medication and been diagnosed with meningiomas. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Mass tort and product cases often involve complex science and procedure. This page explains one piece of the puzzle; a case review addresses how it may apply to you.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewTop Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
